Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
150±302 mm3 compared with 593±328 mm3 for T24 xenograft tumors treated with 5 mg/kg PAI-039 (P<0
so it has IC50 >1 µM for inhibiting demthylation of H3K4 in U2OS human osteosarcoma cell line and in human breast adenocarcinoma MCF7 tumor cell proliferation assay
is a potent and selective small molecule to activate both Oct4 and Nanog promoter-driven luciferase reporter genes
Epub 2011 Sep 22
Dermatol Ther
CPI-444 - CAS# 1202402-40-1 0101 150±302 mm3 compared with 593±328CPI 444, CAS No. 1202402 40 1, is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI 444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine induced
US$ 7250.00
US$ 556.20
US$ 13750.00